Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 4/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118480 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL1503636 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL650656 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL118129 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL18297784 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL23921985 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL375162 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL18297783 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL118128 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL2801944 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2458 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116655469-B | Method for separating and purifying eicosapentaenoic acid ethyl ester by single-column semicontinuous chromatography | 苏州纳微科技股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-3196280-B1 | COMPOSITION CONTAINING EICOSAPENTAENOIC ACID ALKYL ESTER, AND METHOD FOR PRODUCING SAME | NISSUI CORP (JP) | 2026-02-25 | — | — | EP | claimed |
| US-12364679-B2 | Esters for treatment of ocular inflammatory conditions | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2025-07-22 | — | — | US | claimed |
| US-20250186386-A1 | METHODS OF REDUCING THE NEED FOR PERIPHERAL ARTERIAL REVASCULARIZATION IN A STATIN-TREATED SUBJECT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2025-06-12 | — | — | US | claimed |
| EP-4338805-B1 | EICOSAPENTAENOIC ACID ETHYL ESTER FOR USE IN REDUCING THE RISK OF NON-FATAL MYOCARDIAL INFARCTION IN A SUBJECT ON STATIN THERAPY | AMARIN PHARMACEUTICALS IE LTD (IE) | 2025-06-04 | — | — | EP | claimed |
| EP-4342546-B1 | EICOSAPENTAENOIC ACID ETHYL ESTER FOR USE IN REDUCING THE RISK OF NON-FATAL STROKE IN A SUBJECT ON STATIN THERAPY | AMARIN PHARMACEUTICALS IE LTD (IE) | 2025-06-04 | — | — | EP | claimed |
| EP-4556073-A2 | EICOSAPENTAENOIC ACID ETHYL ESTER FOR USE IN REDUCING THE RISK OF NON-FATAL MYOCARDIAL INFARCTION IN A SUBJECT ON STATIN THERAPY | Amarin Pharmaceuticals Ireland Limited (IE) | 2025-05-21 | — | — | EP | claimed |
| EP-4554939-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-05-21 | — | — | EP | claimed |
| CN-119977791-A | Method for separating saturated and unsaturated fatty acid and application thereof | 湖南万全裕湘生物科技有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-115867556-B | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2025-05-06 | — | — | CN | claimed |
| WO-2004078166-A2 | USE OF OMEGA-3-FATTY ACIDS IN THE TREATMENT OF DIABETIC PATIENTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2004-09-16 | — | — | WO | claimed |
| US-20040152778-A1 | Treatment of polyglutamine disorders caused by expanding genomic CAG nucleotides | ODESSA PHARMA | 2004-08-05 | — | — | US | claimed |
| US-20040077723-A1 | Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy | PHARMACIA ITALIA S.P.A. (IT) | 2004-04-22 | — | — | US | claimed |
| EP-1365841-A1 | ESSENTIAL N-3 FATTY ACIDS IN CARDIAC INSUFFICIENCY AND HEART FAILURE THERAPY | Pharmacia Italia S.p.A. (IT) | 2003-12-03 | — | — | EP | claimed |
| EP-1247523-A1 | Essential fatty acids in the prevention of cardiovascular events | Pharmacia Italia S.p.A. (IT) | 2002-10-09 | — | — | EP | claimed |
| WO-2002058793-A1 | ESSENTIAL N-3 FATTY ACIDS IN CARDIAC INSUFFICIENCY AND HEART FAILURE THERAPY | PHARMACIA ITALIA S.P.A. (IT) | 2002-08-01 | — | — | WO | claimed |
| EP-1152755-B1 | ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS | PHARMACIA & UPJOHN SPA (IT) | 2002-04-17 | — | — | EP | claimed |
| EP-1152755-A1 | ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS | PHARMACIA & UPJOHN S.p.A. (IT) | 2001-11-14 | — | — | EP | claimed |
| WO-2000048592-A1 | ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-08-24 | — | — | WO | claimed |
| CN-1204638-A | Preparation of docosahexenoic acid and esterification technology | TIANHAILIN INDUSTRY CO LTD HUN (CN) | 1999-01-13 | — | — | CN | claimed |